Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

[News]

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

More... (http://www.news-medical.net/news/20110401/Alnylam-completes-patient-enrollment-in-ALN-VSP-Phase-I-trial-against-liver-cancer.aspx)